KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Short term Debt (2017 - 2025)

Amneal Pharmaceuticals has reported Short term Debt over the past 9 years, most recently at $7.2 million for Q3 2025.

  • Quarterly results put Short term Debt at $7.2 million for Q3 2025, down 96.79% from a year ago — trailing twelve months through Sep 2025 was $7.2 million (down 96.79% YoY), and the annual figure for FY2024 was $224.2 million, up 25.26%.
  • Short term Debt for Q3 2025 was $7.2 million at Amneal Pharmaceuticals, down from $31.2 million in the prior quarter.
  • Over the last five years, Short term Debt for AMRX hit a ceiling of $225.2 million in Q2 2024 and a floor of $3.9 million in Q3 2022.
  • Median Short term Debt over the past 5 years was $31.2 million (2025), compared with a mean of $82.2 million.
  • Biggest five-year swings in Short term Debt: soared 689.58% in 2023 and later plummeted 96.79% in 2025.
  • Amneal Pharmaceuticals' Short term Debt stood at $47.9 million in 2021, then tumbled by 37.4% to $30.0 million in 2022, then skyrocketed by 497.44% to $179.0 million in 2023, then grew by 25.26% to $224.2 million in 2024, then crashed by 96.79% to $7.2 million in 2025.
  • The last three reported values for Short term Debt were $7.2 million (Q3 2025), $31.2 million (Q2 2025), and $31.8 million (Q1 2025) per Business Quant data.